Antibody structure, instability, and formulation

Journal of Pharmaceutical Sciences

Volumn 96, Issue 1, 2007, Pages 1-26

  Wang, Wei ^a   Singh, Satish ^a   Zeng, David L ^a   King, Kevin ^a   Nema, Sandeep ^a  

^a PFIZER INC   (United States)

Author keywords

Biotechnology; Freeze drying lyophilization; Protein aggregation; Protein formulation; Stabilization

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ARCITUMOMAB TC 99M; BASILIXIMAB; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CETUXIMAB; DACLIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; INFLIXIMAB; INTERLEUKIN 8 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; NATALIZUMAB; NOFETUMOMAB; OKT 3; OMALIZUMAB; ONCOSCINT; ORTHOCLONE OKT; PALIVIZUMAB; PERTUZUMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERLUMA;

ACUTE GRANULOCYTIC LEUKEMIA; ADSORPTION; ANTIBODY AND IMMUNOGLOBULIN STRUCTURE; ANTIBODY STRUCTURE; ASTHMA; B CELL LEUKEMIA; BREAST CANCER; CHEMICAL MODIFICATION; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED RELEASE FORMULATION; CROHN DISEASE; CROSS LINKING; DEAMINATION; DISULFIDE BOND; DRUG FORMULATION; DRUG STABILITY; FRAGMENTATION REACTION; FREEZE DRYING; GLYCATION; HUMAN; ISOMERIZATION; KIDNEY GRAFT REJECTION; MOISTURE; MULTIPLE SCLEROSIS; MUTAGENESIS; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATION; PH; PROTEIN AGGREGATION; PROTEIN DENATURATION; PSORIASIS; RECTUM CARCINOMA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SHORT SURVEY; VIRUS INFECTION;

EID: 33846140780     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20727     Document Type: Short Survey

References (115)

1. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res 18:1345-1353.
2. Roque ACA, Lowe CR, Taipa MA. 2004. Antibodies and genetically engineered related molecules: Production and purification. Biotechnol Prog 20:639-654.
3. Pavlou AK, Belsey MJ. 2005. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 59:389-396.
4. Martsev SP, Tsybovsky YI, Stremovskiy OA, Odintsov SG, Balandin TG, Arosio P, Kravchuk ZI, Deyev SM. 2004. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. Protein Eng Des Sel 17:85-93.
5. Harris RJ, Shire SJ, Winter C. 2004. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res 61:137-154.
6. Janeway CA, Travers PA, Walport M, Shlomchik MJ. 2001. Immunobiology. New York: Garland Publishing.
7. Zhang W, Czupryn MJ. 2002. Free sulfhydryl in recombinant monoclonal antibodies. Biotechnol Prog 18:509-513.
8. Ruzheinikov SN, Muranova TA, Sedelnikova SE, Partridge LJ, Blackburn GM, Murray IA, Kakinuma H, Takahashi-Ando N, Shimazaki K, Sun J, Nishi Y, Rice DW. 2003. High-resolution crystal structure of the Fab-fragments of a family of mouse catalytic antibodies with esterase activity. J Mol Biol 332:423-435.
9. Glockshuber R, Schmidt T, Pluckthun A. 1992. The disulfide bonds in antibody variable domains: Effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry 31:1270-1279.
10. Kroon DJ, Baldwin-Ferro A, Lalan P. 1992. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 9:1386-1393.
11. Wright A, Morrison SL. 1997. Effect of glycosylation on antibody function: Implications for genetic engineering. Trends Biotechnol 15:26-32.
12. Tao MH, Morrison SL. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143:2595-2601.
13. Leibiger H, Wustner D, Stigler RD, Marx U. 1999. Variable domain-linked oligosaccharides of a human monoclonal IgG: Structure and influence on antigen binding. Biochem J 338:529-538.
14. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903.
15. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473.
16. Hunt G, Moorhouse KG, Chen AB. 1996. Capillary isoelectric focusing and sodium dodecyl sulfatecapillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. J Chromatogr A 744:295-301.
17. Jiskoot W, Beuvery EC, de Koning AAM, Herron JN, Crommelin DJA. 1990. Analytical approaches to the study of monoclonal antibody stability. Pharm Res 7:1234-1241.
18. Wang L, Amphlett G, Lambert JM, Blattler W, Zhang W. 2005. Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm Res 22:1338-1349.
19. Wan M, Shiau FY, Gordon W, Wang GY. 1999. Variant antibody identification by peptide mapping. Biotechnol Bioeng 62:485-488.
20. Ramsland PA, Farrugia W. 2002. Crystal structures of human antibodies: A detailed and unfinished tapestry of immunoglobulin gene products. J Mol Recognit 15:248-259.
21. Chen B, Bautista R, Yu K, Zapata GA, Chamow SM, et al. 2003. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm Res 20:1952-1960.
22. Furtado PB, Whitty PW, Robertson A, Eaton JT, Almogren A, Kerr MA, Woof JM, Perkins SJ. 2004. Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: A comparison with monomeric human IgAl. J Mol Biol 338:921-941.
23. Bogard WC, Jr., Dean RT, Deo Y, Fuchs R, Mattis JA, McLean AA, Berger HJ. 1989. Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. Semin Nucl Med 19:202-220.
24. Worn A, Pluckthun A. 1998. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 37:13120-13127.
25. Dall'Acqua W, Simon AL, Mulkerrin MG, Carter P. 1998. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. Biochemistry 37:9266-9273.
26. Chan LA, Phillips ML, Wims LA, Trinh KR, Denham J, Morrison SL. 2004. Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions. Mol Immunol 41:527-538.
27. Morea V, Tramontane A, Rustici M, Chothia C, Lesk AM. 1997. Antibody structure, prediction and redesign. Biophys Chem 68:9-16.
28. Oliva B, Bates PA, Querol E, Aviles FX, Sternberg MJE. 1998. Automated classification of antibody complementarity determining region 3 of the heavy chain (h3) loops into canonical forms and its application to protein structure prediction. J Mol Biol 279:1193-1210.
29. Weir ANC, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson ADG. 2002. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 30:512-516.
30. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. 1993. Humanization of an antibody directed against IgE. J Immunol 151:2623-2632.
31. Sheriff S, Chang CYY, Jeffrey PD, Bajorath J. 1996. X-ray structure of the uncomplexed antitumor antibody br96 and comparison with its antigen-bound form. J Mol Biol 259:938-946.
32. Van Regenmortel MHV. 2002. Reductionism and the search for structure-function relationships in antibody molecules. J Mol Recognit 15:240-247.
33. Lobo ED, Hansen RJ, Balthasar JP. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
34. Coloma MJ, Trinh KR, Wims LA, Morrison SL. 1997. The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J Immunol 158:733-740.
35. Stockwin LH, Holmes S. 2003. Antibodies as therapeutic agents: Vive la renaissance! Expert Opin Biol Ther 3:1133-1152.
36. Cacia J, Keck R, Presta LG, Frenz J. 1996. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity. Biochemistry 35:1897-1903.
37. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752:233-245.
38. Dall'Acqua W, Carter P. 1998. Antibody engineering. Curr Opin Struct Biol 8:443-450.
39. Le Gall F, Reusch U, Little M, Kipriyanov SM. 2004. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 17:85-93.
40. Chu GC, Coulibaly SB, Raibekas A, Deechongkit S. 2005. Protein formulation of an IGG1 antibody with atypical glycosylation: A study on the stability of its glycoforms. Abstr Pap Am Chem Soc 229:U210-U211.
41. Paborji M, Pochopin NL, Coppola WP, Bogardus JB. 1994. Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody. Pharm Res 11:764-771.
42. Welfle K, Misselwitz R, Hausdorf G, Hohne W, Welfle H. 1999. Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. Biochim Biophys Acta 1431:120-131.
43. Li SQ, Bomser JA, Zhang QH. 2005. Effects of pulsed electric fields and heat treatment on stability and secondary structure of bovine immunoglobulin G. J Agric Food Chem 53:663-670.
44. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188.
45. Harrison JS, Gill A, Hoare M. 1998. Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces. Biotechnol Bioeng 59:517-519.
46. Taschner N, Muller SA, Alumella VR, Goldie KN, Drake AF, Aebi U, Arvinte T. 2001. Modulation of antigenicity related to changes in antibody flexibility upon lyophilization. J Mol Biol 310:169-179.
47. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93:1390-1402.
48. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14:1472-1478.
49. Demeule B, Gurny R, Arvinte T. 2005. Where disease pathogenesis meets protein formulation: Renal deposition of immunoglobulin aggregates. Eur J Pharm Biopharm.
50. Ryan ME, Webster ML, Statler JD. 1996. Adverse effects of intravenous immunoglobuin therapy. Clin Pediatr 35:23-31.
51. Schreiber G. 2002. Kinetic studies of protein-protein interactions. Curr Opin Struct Biol 12:41-47.
52. Sukumar M, Doyle BL, Combs JL, Pekar AH. 2004. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res 21:1087-1093.
53. Levine HL, Ransohoff TC, Kawahata RT, McGregor WC. 1991. Use of surface tension measurements in the design of antibody-based product formulations. J Parenter Sci Technol 45:160-165.
54. Ferri C, Zignego AL, Pileri SA. 2002. Cryoglobulins. J Clin Pathol 55:4-13.
55. Lam XM, Oeswein JQ, Ongpipattanakul B, Shahrokh Z, Wang SX, Weissburg RP, Wong RL. 2000. Stabilized Antibody Formulation. Genentech, Inc., US Patent US 6991790 B1.
56. Lee LS. 1997. Stabilized monomeric protein compositions. Enzon, Inc., US Patent US 5656730.
57. Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90:310-321.
58. Hagiwara H, Yuasa H, Yamamoto Y. 2000. Stabilized human monoclonal antibody preparation, Yoshihide Hagiwara.
59. Ressing ME, Jiskoot W, Talsma H, Van Ingen CW, Crommelin DJ, et al. 1992. Influence of sucrose, dextran, and hydroxypropyl-beta-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG2a monoclonal antibody (MN12). Pharm Res 9:266-270.
60. Roy ML, Pikal MJ, Rickard EC, Maloney AM. 1992. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: A test of the WLF glass transition theory. Dev Biol Stand 74:323-339; discussion 340.
61. Kamat MS, Tolman GL, Brown JM. 1996. Formulation development of an antifibrin monoclonal antibody, radiopharmaceutical. Pharm Biotechnol 9:343-364.
62. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 5:E10.
63. Riggin A, Clodfelter D, Maloney A, Rickard E, Massey E. 1991. Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB. Pharm Res 8:1264-1269.
64. Duddu SP, Dal Monte PR. 1997. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm Res 14:591-595.
65. Maa YF, Nguyen PA, Andya JD, Dasovich N, Hsu CC, et al. 1998. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm Res 15:768-775.
66. Maa YF, Nguyen PA, Hsu SW. 1998. Spray-drying of air-liquid interface sensitive recombinant human growth hormone. J Pharm Sci 87:152-159.
67. Alexander AJ, Hughes DE. 1995. Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem 67:3626-3632.
68. Hartmann WK, Saptharishi N, Yang XY, Mitra G, Soman G. 2004. Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performance liquid chromatography with quadruple detection. Anal Biochem 325:227-239.
69. Doran PM. 2006. Loss of secreted antibody from transgenic plant tissue cultures due to surface adsorption. J Biotechnol 122:39-54.
70. Morales AA, Nunez-Gandolff G, Perez NP, Veliz BC, Caballero-Torres I, Duconge J, Fernandez E, Crespo FZ, Veloso A, Iznaga-Escobar N. 1999. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: Additives, biodistribution, and stability. Nucl Med Biol 26:717-723.
71. Andya JD, Maa YF, Costantino HR, Nguyen PA, Dasovich N, Sweeney TD, Hsu CC, Shire SJ. 1999. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res 16:350-358.
72. Usami A, Ohtsu A, Takahama S, Fujii T. 1996. Effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J Pharm Biomed Anal 14:1133-1140.
73. Rao PE, Kroon DJ. 1993. Orthoclone OKT3 chemical mechanims and functional effects of degradation of a therapeutic monoclonal antibody. In: Pearlman R, Wan YJ, editors. Stability and characterization of protein and peptide drugs case histories. New York: Plenum Press, p. 135-158.
74. Tous GI, Wei Z, Feng J, Bilbulian S, Bowen S, Smith J, Strouse R, McGeehan P, Casas-Finet J, Schenerman MA. 2005. Characterization of a novel modification to monoclonal antibodies: Thioether cross-link of heavy and light chains. Anal Chem 77:2675-2682.
75. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10:307-377.
76. Xie M, Schowen RL. 1999. Secondary structure and protein deamidation. J Pharm Sci 88:8-13.
77. Kwong MY, Harris RJ. 1994. Identification of succinimide sites in proteins by N-terminal sequence analysis after alkaline hydroxylamine cleavage. Protein Sci 3:147-149.
78. Zheng JY, Janis LJ. 2005. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int J Pharm 308:46-51.
79. Tyler-Cross R, Schirch V. 1991. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem 266:22549-22556.
80. Johnson RE, Qi H, Borgmeyer JR, Kessler RK, Zeng DL. 2004. Stable pH optimized formulation of a modified antibody. Pharmacia Corporation. International patent Wo2004/019861 A2.
81. Lam XM, Yang JY, Cleland JL. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86:1250-1255.
82. Harris RJ. 1995. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A 705:129-134.
83. Powell MF. 1996. A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: Reactivity at Asn, Asp, Gln, and Met motifs in neutral pH solution. In: Pearlman R, Wang YJ, editors. Formulation, characterization, and stability of protein drugs. New York: Plenum Press. p. 1-140.
84. Sarno MEC, Vasquez RA, Yung S-G, Graf CR. 1999. Stable intravenously-administrable immune globulin preparation. Baxter International Inc., US patent US5945098.
85. Caballero I, Altanes S, Castillo A, Deridder V, Gomez T, Miralles Y, Naydenov V, Prieto E, Tilquin B. 2004. Radiosensitivity study of freeze-dried antibodies to Gamma irradiation. Ame Pharm Rev 7:40-46, 81.
86. Kennedy DM, Skillen AW, Self CH. 1994. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin Exp Immunol 98:245-251.
87. Patten PA, Schellekens H. 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel) 112:81-97.
88. Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94:1928-1940.
89. Golovanov AP, Hautbergue GM, Wilson SA, Lian LY. 2004. A simple method for improving protein solubility and long-term stability. J Am Chem Soc 126:8933-8939.
90. Kueltzo LA. 2004. Aggregation of monoclonal antibodies in aqueous solution with and without agitation. Formulation Strategies for Protein Therapeutics. Boston, MA: IBC Life Sciences.
91. Mahler HC, Muller R, Friebeta W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59:407-417.
92. Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19:511-516.
93. Ha E, Wang W, Wang YJ. 2002. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 91:2252-2264.
94. Gupta S, Kaisheva E. 2003. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS PharmSci 5:E8.
95. Kocijan A, Milosev I, Pihlar B. 2003. The influence of complexing agent and proteins on the corrosion of stainless steels and their metal components. J Mater Sci Mater Med 14:69-77.
96. McCormick D. 2004. Small changes, big effects in biological manufacturing. Pharm Technol 28:16.
97. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14:969-975.
98. Wang W. 2000. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203:1-60.
99. Akers MJ, Vasudevan V, Stickelmeyer M. 2002. Formulation development of protein dosage forms. Pharm Biotechnol 14:47-127.
100. Chang BS, Hershenson S. 2002. Practical approaches to protein formulation development. Pharm Biotechnol 13:1-25.
101. Chang LL, Shepherd D, Sun J, Ouellette D, Grant KL, Tang XC, Pikal MJ. 2005. Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J Pharm Sci 94:1427-1444.
102. Chang LL, Shepherd D, Sun J, Tang XC, Pikal MJ. 2005. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. J Pharm Sci 94:1445-1455.
103. Pikal MJ, Rigsbee DR. 1997. The stability of insulin in crystalline and amorphous solids: Observation of greater stability for the amorphous form. Pharm Res 14:1379-1387.
104. Crowe JH, Crowe LM, Carpenter JF. 1993. Preserving dry biomaterials: The water replacement hypothesis, part 1. Biopharm 6:28-37.
105. Crowe JH, Crowe LM, Carpenter JF. 1993. Preserving dry biomaterials: The water replacement hypothesis, part 2. Biopharm 6:40-43.
106. Shenoy B, Wang Y, Shan W, Margolin AL. 2001. Stability of crystalline proteins. Biotechnol Bioeng 73:358-369.
107. Andya J, Cleland JL, Hsu CC, Lam XM, Overcashier DE, Shire SJ, Yang JY-F, Wu SS-Y. 2004. Protein formulation. Genentech, Inc.
108. Ma X, Wang DQ, Bouffard R, MacKenzie A. 2001. Characterization of murine monoclonal antibody to tumor necrosis factor (TNF-MAb) formulation for freeze drying cycle development. Pharm Res 18:196-202.
109. Maa YF, Costantino HR, Nguyen PA, Hsu CC. 1997. The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm Dev Technol 2:213-223.
110. Maury M, Murphy K, Kumar S, Mauerer A, Lee G. 2005. Spray-drying of proteins: Effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharm Biopharm 59:251-261.
111. Krauss J, Arndt MA, Zhu Z, Newton DL, Vu BK, Choudhry V, Darbha R, Ji X, Courtenay-Luck NS, Deonarain MP, Richards J, Rybak SM. 2004. Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme. Br J Cancer 90:1863-1870.
112. McIntosh DP, Cooke RJ, McLachlan AJ, Daley-Yates PT, Rowland M. 1997. Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. J Pharm Sci 86:1478-1483.
113. Yewey GL, Duysen EG, Cox SM, Dunn RL. 1997. Delivery of proteins from a controlled release injectable implant. Pharm Biotechnol 10:93-117.
114. Porjazoska A, Goracinova K, Mladenovska K, Glavas M, Simonovska M, Janjevic EI, Cvetkovska M. 2004. Poly(lactide-co-glycolide) microparticles as systems for controlled release of proteins-preparation and characterization. Acta Pharm 54:215-229.
115. Homayoun P, Mandal T, Landry D, Komiskey H. 2003. Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres. J Pharm Pharmacol 55:933-938.